Based on this hyper-inflammatory pathogenic background, targeting upstream molecules in the inflammatory cascade such as IL-1 and IL-6 soon appeared as a promising therapeutic strategy to contrast the progression of severe COVID-19, and high hopes were placed on the IL-1 and IL-6 blocking agents anakinra, tocilizumab, and sarilumab (3–10). The gene discussed is IL1A; the disease is COVID-19.